Rivastigmine effect on mild cognitive impairment patients decision making

Phase 3

Recruiting

• Conditions: Mild Cognitive Impairment (MCI).; Mild cognitive impairment, so stated; G31.84

• Registration Number: IRCT20201104049257N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 May 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Mild cognitive impairment diagnosis on Functional Assessment Staging Test (FAST)=3
Age more than 40
Third grade education
Mini-mental state examination between 24 to 30

Exclusion Criteria

Psychiatric disorder history
Untreated depression
Vitamin b12 deficiency
Uncontrol hypothyroidism
Drug abuse during 6 month ago
Seizure history
Major neurologic disorder
Stroke
Cholinesterase inhibitor administration during 6 month ago
Other disease interfere with decision making
Heart block, bradycardia (heart rate<60)
Gastrointestinal bleeding during 6 month ago
Pregnancy and lactation
Rivastigmine allergy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Effect on decision making. Timepoint: 3 months from the start of the intervention. Method of measurement: CANTAB test including CGT (Gambling Cambridge Test) ?IST (Information Task Sampling) ? SST (Stop Signal Task).

Secondary Outcome Measures

Name	Time	Method
Adverse event evaluation. Timepoint: Every two weeks. Method of measurement: Ask questions of the patient and record information.